# Treatment Methods for Pompe Disease
The treatment of Pompe disease focuses on replacing or supplementing the missing enzyme glucosidase (GAA), and on supportive care for specific symptoms. The approach differs depending on the type and stage of the disease.
Enzyme Replacement Therapy (ERT)
ProveniIncluded in official guidelines, or approved by EMA or FDA
Enzyme replacement therapy is the standard treatment for both the infantile and late-onset forms of Pompe disease. The missing enzyme α-glucosidase is administered intravenously via infusion, usually at home or in a hospital. The enzyme can break down glycogen in the muscles and heart, reducing accumulation.
The duration of action of an infusion is limited (a few weeks), so infusions are repeated regularly. This requires an ongoing commitment to infusion appointments. Research shows that this therapy is particularly effective in the early phase of the infantile form, especially for preventing progression of heart problems. In late-onset Pompe, the progression of muscle weakness can be slowed, but not always completely halted.
Known side effects are infusion-related reactions (such as fever, chills, headache or shortness of breath), which occur because the body sometimes attacks the administered enzyme as foreign. These reactions may decrease with repetition or can be mitigated. Very rarely, allergies or more serious hypersensitivity reactions develop.
For patients whose body produces high levels of antibodies against the enzyme, the therapy may become less effective ('tachyphylaxis'). In these situations, other enzyme variants (see below) may be considered, although there is no guarantee they will work better.
ProveniIncluded in official guidelines, or approved by EMA or FDA
A relatively new variant of enzyme replacement therapy uses cipaglucosidase alfa, an enzyme molecule that is less rapidly eliminated by previous antibody formation. Studies compare this drug with traditional ERT and investigate whether it is better able to prevent progression in the long term. This is also administered via infusion and can cause the same infusion-related reactions.
ProveniIncluded in official guidelines, or approved by EMA or FDA
Avalglucosidase alfa is an enzyme molecule that binds more strongly to muscles than traditional forms. This can offer advantages in certain scenarios, especially for patients whose disease progresses under standard therapy. This form is also given intravenously and can cause infusion-related reactions.
Additional Medication: Miglustat
ResearchediPositive results in clinical studies, not yet standard treatment
Miglustat is a substance that can slow down the formation of glycogen in body cells. The idea is that by producing less glycogen, less glycogen also needs to be broken down. In combination with enzyme replacement therapy, this drug is being investigated in some patients for potential benefits in stabilizing muscle and lung function. Evidence for added benefit is still under investigation.
Side effects of miglustat can include diarrhea, weight loss, and peripheral neuropathy (nerve damage in the arms and legs).
Gene therapy
ExperimentaliOngoing in study setting, outcome still unknown
Gene therapy for Pompe disease is in various stages of development and clinical investigation. The basic principle is that a correctly functioning copy of the GAA gene is introduced into muscle or heart muscle cells via a virus (usually an adeno-associated virus, AAV), so that the body itself produces the enzyme.
Studies in animals show that this can in principle be effective, especially for preventing or reducing heart enlargement in very young newborns. Clinical studies in humans are underway.
Gene therapy is not yet approved as standard treatment, but various patients with the infantile form have participated in it. Long-term safety and efficacy are still being investigated. Possible side effects under investigation include inflammatory reactions of the body to the virus itself, and theoretical risks of integration sites in DNA (although the AAV variants used typically do not integrate into DNA).
Respiratory support
ProveniIncluded in official guidelines, or approved by EMA or FDA
For patients with progressive weakness of respiratory muscles, mechanical ventilation may be necessary. This can start with nighttime support (for example via a mask) and in severe cases evolve into more intensive forms.
Recent research suggests that certain respiratory problems in late-onset Pompe present differently than initially thought, particularly in the exhalation phase. This may be relevant for the choice of ventilation mode. Respiratory monitoring is part of regular care.
Cardiological care
ProveniIncluded in official guidelines, or approved by EMA or FDA
Patients with the infantile form typically require intensive cardiac monitoring, due to the risk of severe cardiac enlargement and arrhythmias. This includes regular echocardiography and electrocardiograms.
Medications to support heart function (such as ACE inhibitors or beta-blockers) can be used based on a cardiologist's advice. Enzyme replacement therapy itself works primarily to prevent heart damage.
Muscle and physical therapy
ProveniIncluded in official guidelines, or approved by EMA or FDA
Physiotherapy and exercise are recommended to counteract muscle wasting and maintain mobility for as long as possible. This includes gentle exercises, stretching, and guidance in adapting daily activities as muscle weakness increases.
Orthotic aids (foot supports, back braces) can support mobility.
Nutrition and digestion
ProveniIncluded in official guidelines, or approved by EMA or FDA
Swallowing difficulties can occur, especially in the infantile form. Speech therapy and dietary guidance help ensure safe nutrition. In severe cases, tube feeding may be necessary.
Monitoring and diagnostic tests
ProveniIncluded in official guidelines, or approved by EMA or FDA
Regular monitoring is essential for all patients to detect progression and assess response to therapy. This includes:
- Blood and urine tests for markers of muscle breakdown (creatine kinase, myoglobin)
- Spirometry for lung function
- Echocardiography and ECG for heart function
- Mobility and strength tests
- Sometimes muscle biopsies or MRI scans
New biomarkers (such as electrical impedance of muscles) are being investigated to better detect progression.
Supportive care
ProveniIncluded in official guidelines, or approved by EMA or FDA
Psychological support, social services, and coordination with other specialists (neurology, cardiology, respiratory medicine) are part of good treatment management. This is especially important given the progressive nature and impact on daily functioning.
---
_This information never replaces a doctor's judgment. Always discuss your situation with your own healthcare provider._